Save on Asciminib with Coupons, Discounts & Savings Programs

Asciminib is available as a 20 mg and 40 mg oral tablet.

Asciminib is a tyrosine kinase inhibitor and is used to treat Philadelphia-positive chronic myelogenous leukemia (Ph+ CML).

Asciminib is a tyrosine kinase inhibitor (TKI). It blocks a certain protein in your body called BCR-ABL tyrosine kinase. This protein is found on cancer cells like CML and not on normal, healthy cells. It causes the cancer cells to grow and multiply. By blocking this protein, Asciminib kills cancer cells and stops their spread.

The typical starting dose of Asciminib is 80 mg taken by mouth once daily. Another recommended option is to take 40 mg twice daily, about 12 hours apart. If you have the T315I mutation in your cancer, the recommended starting dose is 200 mg taken by mouth twice daily, about 12 hours apart.

Asciminib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Asciminib:

• Bone or muscle pain
• Tiredness
• Rash
• Infection in your sinuses or throat
• Nausea
• Diarrhea

Serious side effects are rare with Asciminib. Contact your healthcare provider immediately if you experience any of the following.

• Heart or blood vessel problems: shortness of breath; chest pain; fast heartbeat; swelling in your ankles or feet; numbness on one side of your body; vision changes; severe stomach area pain; pain in your arms, legs, back, neck, or jaw

The following medications may interact with Asciminib:

• Strong CYP3A4 Inhibitors: Closely monitor for adverse reactions during concomitant use of Asciminib at 200 mg twice daily.
• Itraconazole Oral Solution Containing Hydroxypropyl-β-cyclodextrin: Avoid concomitant use of Asciminib at all recommended doses
• Certain Substrates of CYP3A4: Closely monitor for adverse reactions during concomitant use of Asciminib at 80 mg total daily dose. Avoid use of Asciminib at 200 mg twice daily
• Substrates of CYP2C9: Avoid concomitant use of Asciminib at all recommended doses
• 80 mg total daily dose: If unavoidable, reduce the CYP2C9 substrate dosage as necessary
• 200 mg twice daily: If unavoidable, consider alternative therapy with non-CYP2C9 substrate
• Certain P-gp Substrates: Closely monitor for adverse reactions during concomitant use of Asciminib at all recommended doses
• Substrates of OATP1B or BCRP: Avoid concomitant use with rosuvastatin and atorvastatin at all recommended doses. Closely monitor for adverse reactions of other OATP1B or BCRP substrates during concomitant use of
• Asciminib at all recommended doses

Various FDA-approved generic manufacturers

Asciminib can harm your unborn baby. Your healthcare provider will do a pregnancy test before you start treatment with Asciminib. Females who are able to become pregnant should use effective birth control during treatment and for 1 week after your last dose of Asciminib. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Asciminib.

• Scemblix